Compare NUS & FHTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NUS | FHTX |
|---|---|---|
| Founded | 1984 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 343.1M | 323.4M |
| IPO Year | 1996 | 2020 |
| Metric | NUS | FHTX |
|---|---|---|
| Price | $7.23 | $4.81 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.50 |
| AVG Volume (30 Days) | ★ 365.3K | 110.0K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.36% | N/A |
| EPS Growth | ★ 207.80 | 25.32 |
| EPS | ★ 3.18 | N/A |
| Revenue | ★ $3,176,718,000.00 | $30,909,000.00 |
| Revenue This Year | N/A | $8.89 |
| Revenue Next Year | $7.14 | $20.13 |
| P/E Ratio | $2.30 | ★ N/A |
| Revenue Growth | ★ 48.98 | 36.75 |
| 52 Week Low | $5.63 | $3.27 |
| 52 Week High | $14.62 | $6.95 |
| Indicator | NUS | FHTX |
|---|---|---|
| Relative Strength Index (RSI) | 40.70 | 42.62 |
| Support Level | $7.03 | $4.44 |
| Resistance Level | $8.08 | $5.82 |
| Average True Range (ATR) | 0.23 | 0.27 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 11.86 | 13.54 |
Nu Skin Enterprises Inc develops and distributes a comprehensive line of beauty and wellness solutions in various countries. The company operates in two primary product categories: beauty and wellness products. Additionally, the company also operates through its subsidiary, Rhyz. It reports revenue from nine segments, consisting of its seven geographic Nu Skin segments: Americas, Southeast Asia/Pacific, Mainland China, Japan, Europe & Africa, South Korea, and Hong Kong/Taiwan and two Rhyz segments: manufacturing, which includes manufacturing and packaging subsidiaries it has acquired; and Rhyz Other, which includes other investments by its Rhyz strategic investment arm. The majority of the company's revenue is generated from the Wellness product category from the Americas segment.
Foghorn Therapeutics Inc is a clinical stage, precision therapeutics biotechnology company focused on pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression through selectively targeting the chromatin regulatory system. Its proprietary platform is designed to provide an integrated, mechanistic understanding of interactions within the chromatin regulatory system, supporting the identification and validation of potential therapeutic targets. The company's flagship program is FHD-909.